In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, GoodRx Holdings Inc’s stock clocked out at $3.83, down -1.79% from its previous closing price of $3.9. In other words, the price has decreased by -$1.79 from its previous closing price. On the day, 2.03 million shares were traded. GDRX stock price reached its highest trading level at $3.91 during the session, while it also had its lowest trading level at $3.81.
Ratios:
To gain a deeper understanding of GDRX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.73 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.02. For the most recent quarter (mrq), Quick Ratio is recorded 4.21 and its Current Ratio is at 4.21. In the meantime, Its Debt-to-Equity ratio is 0.85 whereas as Long-Term Debt/Eq ratio is at 0.84.
On December 04, 2024, Mizuho started tracking the stock assigning a Neutral rating and target price of $5.
Raymond James Upgraded its Outperform to Strong Buy on August 09, 2024, while the target price for the stock was maintained at $10.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 15 ’25 when Spectrum Equity VII, L.P. sold 23,771 shares for $4.00 per share. The transaction valued at 95,103 led to the insider holds 0 shares of the business.
Spectrum VII Co-Investment Fun bought 8,569 shares of GDRX for $34,447 on Oct 15 ’25. On Oct 15 ’25, another insider, Spectrum VII Investment Manage, who serves as the Affiliate of the company, bought 15,202 shares for $4.02 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GDRX now has a Market Capitalization of 1330733440 and an Enterprise Value of 1596953472. As of this moment, GoodRx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 41.27, and their Forward P/E ratio for the next fiscal year is 8.40. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.63. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.66 while its Price-to-Book (P/B) ratio in mrq is 2.10. Its current Enterprise Value per Revenue stands at 1.997 whereas that against EBITDA is 11.863.
Stock Price History:
The Beta on a monthly basis for GDRX is 1.22, which has changed by -0.4205749 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, GDRX has reached a high of $6.97, while it has fallen to a 52-week low of $3.31. The 50-Day Moving Average of the stock is -8.66%, while the 200-Day Moving Average is calculated to be -14.25%.
Shares Statistics:
It appears that GDRX traded 4.44M shares on average per day over the past three months and 6880550 shares per day over the past ten days. A total of 99.90M shares are outstanding, with a floating share count of 81.47M. Insiders hold about 76.55% of the company’s shares, while institutions hold 15.98% stake in the company. Shares short for GDRX as of 1759190400 were 6269859 with a Short Ratio of 1.41, compared to 1756425600 on 6679799. Therefore, it implies a Short% of Shares Outstanding of 6269859 and a Short% of Float of 7.180000000000001.
Earnings Estimates
A detailed examination of GoodRx Holdings Inc (GDRX) is currently in progress, with 12.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.1, with high estimates of $0.11 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.4 and $0.34 for the fiscal current year, implying an average EPS of $0.37. EPS for the following year is $0.46, with 12.0 analysts recommending between $0.51 and $0.39.
Revenue Estimates
In. The current quarter, 13 analysts expect revenue to total $194.51M. It ranges from a high estimate of $197.48M to a low estimate of $192.54M. As of. The current estimate, GoodRx Holdings Inc’s year-ago sales were $195.25MFor the next quarter, 13 analysts are estimating revenue of $197.6M. There is a high estimate of $202.12M for the next quarter, whereas the lowest estimate is $194.1M.
A total of 15 analysts have provided revenue estimates for GDRX’s current fiscal year. The highest revenue estimate was $804.6M, while the lowest revenue estimate was $794.01M, resulting in an average revenue estimate of $797.96M. In the same quarter a year ago, actual revenue was $792.32MBased on 15 analysts’ estimates, the company’s revenue will be $840.24M in the next fiscal year. The high estimate is $871.41M and the low estimate is $816.1M.
